Global Information
회사소개 | 문의 | 위시리스트

세계의 세포치료 시장 : 가격, 제품, 임상 파이프라인 전망

Global Cell Therapy Market, Price, Product & Clinical Pipeline Outlook 2024

리서치사 KuicK Research
발행일 2018년 04월 상품 코드 302594
페이지 정보 영문 1200 Pages
가격
US $ 2,400 ₩ 2,833,000 Unprintable PDF by E-mail (Single User License)
US $ 3,300 ₩ 3,896,000 CD-ROM
US $ 3,800 ₩ 4,487,000 Hard Copy
US $ 4,800 ₩ 5,667,000 Printable PDF by E-mail (Multi-User License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 세포치료 시장 : 가격, 제품, 임상 파이프라인 전망 Global Cell Therapy Market, Price, Product & Clinical Pipeline Outlook 2024
발행일 : 2018년 04월 페이지 정보 : 영문 1200 Pages

세계의 세포치료 시장에 대해 조사분석했으며, 시장 분석, 인사이트, 시장 기회, 출시 제품, 지역/국가별 분석, 임상 파이프라인, 경쟁 구도 등의 정보를 정리하여 전해드립니다.

제1장 세포치료란?

제2장 세포치료의 기서

  • 세포치료의 원리
  • 표면 마커·표적의 역할
  • 동종줄기세포 요법
  • 자가줄기세포 요법

제3장 줄기세포 : 세포치료 시장 확립에서의 응용과 기여

  • 줄기세포의 유래
  • 줄기세포 능력으로 차별화

제4장 세포치료 시장 : 치료 분야에서의 적응별

  • 심혈관질환
  • 신경질환
  • 염증성 질환

제5장 미국에서 승인된 세포치료의 제품·가격 분석

  • Apligraf & Dermagraft
  • Carticel
  • ChondroCelect
  • Epicel
  • Holoclar
  • Kymriah
  • Provenge
  • Yescarta

제6장 유럽에서 승인된 세포치료의 제품·가격 분석

  • Spherox
  • Strimvelis

제7장 한국에서 승인된 세포치료의 제품·가격 분석

  • Cartistem
  • Cupistem
  • Hearticellgram

제8장 일본에서 승인된 세포치료의 제품·가격 분석

  • HeartSheet
  • Temcell

제9장 세계 세포치료 시장의 현황

제10장 세계 세포 시장의 동향

제11장 세포치료 부문의 협업·인수

제12장 세포치료 시장의 지역별 분석

  • 북미
  • 유럽
  • 아시아
  • 기타

제13장 세포치료 시장 역학

제14장 세포치료 시장의 향후 전망

제15장 세계 세포치료의 임상 파이프라인 : 기업별, 적응별, 상별

  • 불명
  • 연구
  • 전임상
  • 임상
  • 제0상
  • 제I상
  • 제I/II상
  • 제II상
  • 제II/III상
  • 제III상
  • 신청
  • 승인

제16장 출시 세포치료의 임상 인사이트

제17장 경쟁 구도

  • AlloCure
  • Arteriocyte Medical Systems
  • Athersys Inc.
  • Baxter Healthcare Corporation
  • Bone Therapeutics
  • Celgene Corporation
  • Cell Medica
  • Cellerant Therapeutics
  • FibrocellScinence
  • Forticell Bioscience
  • Genzyme Corporation
  • Green Cross Cell
  • Histogenics Corporation
  • InnovacellBiotechnologie AG
  • Intrexon Corporation
  • Intercytex
  • ISTO Technologies
  • Macrocure
  • Mesoblast
  • Molmed
  • Nuo Therapeutics Inc
  • OmniCyte
  • Opexa Therapeutics
  • Organogenesis
  • Pharmicell
  • TCA Cellular Therapy
  • Stem Cell Inc.
  • Teva Pharmaceuticals
  • Tigenix
  • Vericel Corporation
KSA 18.05.09

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

"Global Cell Therapy Market, Price, Product & Clinical Pipeline Outlook 2024" Report Highlights:

  • Market Analysis by Application in Various Therapeutic Areas
  • Comprehensive Insight On Clinical Pipeline: 664 Cell Therapies
  • Cell Therapy Market Opportunity More Than US$ 25 Billion by 2024
  • Marketed Cell Therapies: 21
  • Price & Product Insight By Region/Country
  • Cell Therapy Clinical Pipeline Overview
  • Collaborations & Acquisition in the Cell Therapy Segment
  • Regional Analysis of the Cell Therapy Market

Cell therapy is an integral part of immunotherapy that has shown excellent therapeutic ability in several clinical indications. In recent years, studies regarding the use of cells for their therapeutic ability have gained immense popularity in the scientific and healthcare research community. The segment currently flourishes with several techniques like CAR-T cell therapy, Stem cell therapy, and cord blood cell therapy with each of them gaining extreme popularity due to their wide application in several clinical indications such as cancer, cardiovascular disease and cancer.

The most popular and common technique of cell therapy aims at using healthy cells from a compatible donor (Allogeneic) or from the patient itself (Autogenic) and their modification to amplify their therapeutic ability. It involves complex steps like genetic screening of cell, modification of cell by genetic sequencing, their harvesting and reinfusion into the patient's body. Each of these steps plays a vital role in the therapeutic outcome, thus leading to the establishment of the cell therapy market.

Stem cell therapy is currently the dominant segment in the cell therapy market with maximum success rate reported globally. Their special ability to differentiate into any type of cell without losing their identity makes them the most promising therapeutic entities of the future. Researchers claim that stem cells are bound to revolutionize regenerative medicine with it being applied in the treatment of complex disease such as cardiovascular disease, neurodegenerative disease, inflammatory disease and cancer.

Moreover, researchers assume that modification of cell therapy techniques could result in potential cures for multiple sclerosis, diabetes, spinal cord injury, cancer, heart disease, Parkinson's disease, Alzheimer's disease, and immune system disorders. The role of cell therapy and stem cell research will also be most helpful in the therapeutic sectors of cloning and regenerative medicine

Cell therapy based products like Kymriah, Provenge and Yescarta have been well received in the market inspite of their hefty price tag; costing well over US$ 100,000 which clearly indicates the lucrative nature of the cell therapy market. Innovations in pharmaceutical and biotechnology research are the key driving parameters for the development of cell therapies. For instance, holoclar treatment for curing blindness, cartistem for cartilage cell regeneration and Epicel for burn wound replacement have shown excellent outcome in their initial clinical studies which could become the gold standard therapeutics of the future.

Investigators have been able to identify different stem cell sources which offers them large base for developing new therapies. Majority of the cell therapy techniques can be customized according to a patient's requirement thus making it a leading segment in personalized therapy. As a result, large numbers of stem cell therapies are entering in clinical trials across the globe. They are at different stages of development and likely to be introduced in global market in coming years. This will help the stem cell therapy developers to generate significant revenues in coming years.

Inspite of several challenges restraining the growth of the cell therapy market, experts claim the segment to be a burgeoning market of the future. This claim is supported by the fact that more than 150 companies globally have invested over US$ 1 Billion in the fairly new industry. Active participation of countries like Japan, South Korea, China and India has made it a progressive market of the future with widely untapped potential.

Kuick Research Report on the Global cell therapy market provides a detailed insight into the current scenario of the cell therapy market worldwide. Key data like pricing of cell therapy products, cost analysis of cell therapy procedures, adoption rate, current market trends and recent developments that might impact the cell therapy market are also highlighted in the report. Further, extensive analysis using data from primary and secondary source has been used for the effective forecast and future projections regarding the cell therapy market.

Table of Contents

1. Prologue to Cell Therapy

  • 1.1 An Overview to Cells & Their Therapeutic Ability
  • 1.2 Unique Features of Cellular Therapeutics
    • 1.2.1 Stem Cells - Key Agents of Cellular Based Therapeutics
    • 1.2.2 Key Advantages of Cell Therapy over Other Existing Therapeutics

2. Mechanism of Cell Therapy Treatment

  • 2.1 Principle of Cell Therapy
    • 2.1.1 Cell Therapy & the Immune Response
    • 2.1.2 Mechanism of Regenerative Cell Therapy
  • 2.2 Role of Surface Markers & Their Targeting
    • 2.2.1 Targeting the Signal Cascades
    • 2.2.2 Targeting the Microenvironment
  • 2.3 Allogeneic Stem Cell Therapy
  • 2.4 Autologous Stem Cell Therapy

3. Stem Cells - Their Application & Contribution in the Establishment of Cell Therapy Market

  • 3.1 Origin of Stem Cells
    • 3.1.1 Embryonic Stem Cells
    • 3.1.2 Adult Stem Cells
    • 3.1.3 Induced Pluripotent Stem Cells (iPSCs)
  • 3.2 Exploring Stem Cell's Ability to Differentiate
    • 3.2.1 Totipotent Stem Cells
    • 3.2.2 Pluripotent Stem Cells
    • 3.2.3 Multipotent Stem Cells
    • 3.2.4 Unipotent Stem Cells

4. Cell Therapy Market Analysis by Application in Various Therapeutic Areas

  • 4.1 Cell Therapy for Cardiovascular Disease
    • 4.1.1 Myocardial Infarction
    • 4.1.2 Heart Failure
  • 4.2 Cell Therapy for Neurological Disorders
    • 4.2.1 Parkinson's Diseases
    • 4.2.2 Alzheimer's Diseases
    • 4.2.3 Huntington's Diseases
  • 4.3 Cell Therapy for Inflammatory Diseases
    • 4.3.1 Asthma
    • 4.3.2 Arthritis
    • 4.3 Cell Therapy for Diabetes
    • 4.3.3 Type 1 diabetes
    • 4.3.4 Type 2 diabetes
  • 4.4 Cell Therapy for Cancer
    • 4.4.1 Stem Cells & Their Therapeutic Role in Cancer
    • 4.4.2 Role of Surface Markers & Their Targeting
    • 4.4.3 Targeting the Signal Cascades
    • 4.4.4 Targeting the Microenvironment

5. Product & Price Analysis of Cell Therapy Approved in US

  • 5.1 Apligraf & Dermagraft
  • 5.2 Carticel
  • 5.3 ChondroCelect
  • 5.4 Epicel
  • 5.5 Holoclar
  • 5.6 Kymriah
  • 5.7 Provenge
  • 5.8 Yescarta

6. Product & Price Analysis of Cell Therapy Products Approved in Europe

  • 6.1 Spherox
  • 6.2 Strimvelis

7. Product & Price Analysis of Cell Therapy Approved in South Korea

  • 7.1 Cartistem
  • 7.2 Cupistem
  • 7.3 Hearticellgram

8. Product & Price Analysis of Cell Therapy Approved in Japan

  • 8.1 HeartSheet
  • 8.2 Temcell

9. Current Status of the Global Cell Therapy Market

  • 9.1 Overview of the Global Cell Therapy Market
  • 9.2 Industrial Insight into the Cell Therapy Market - Key Players & Their Contribution
  • 9.3 Cell Therapy Clinical Pipeline Overview
  • 9.4 Investments in the Cell Therapy Market

10. Global Cell Therapy Market Trends

  • 10.1 Cell Therapy Enhancing the Effect of Existing Therapeutic Methods
  • 10.2 Cell Therapy Market More Oriented Towards Immune Cells
  • 10.3 Involvement of Both Academia & Industries to Enhance Progress of Cell Therapy Studies
  • 10.4 Impact of Cell Therapy on the Drug Delivery Market
  • 10.4.1 Direct Delivery Methods
  • 10.4.2 Indirect Delivery Method

11. Collaborations & Acquisition in the Cell Therapy Segment

  • 11.1 Collaborations
  • 11.2 Acquisition

12. Regional Analysis of the Cell Therapy Market

  • 12.1 North America
  • 12.2 Europe
  • 12.3 Asia
    • 12.3.1 China
    • 12.3.2 Japan
    • 12.3.3 South Korea
    • 12.3.4 India
  • 12.4 Rest of the World
    • 12.4.1 Africa
    • 12.4.2 Middle East
    • 12.4.3 South America

13. Global Cell Therapy Market Dynamics

  • 13.1 Growth Promoting Parameters of the Cell Therapy Market
  • 13.2 Commercial Challenges of the Cell Therapy Market

14. Future Prospectus & Scope of the Cell Therapy Market

15. Global Cell Therapy Clinical Pipeline by Company, Indication & Phase

  • 15.1 Unknown
  • 15.2 Research
  • 15.3 Preclinical
  • 15.4 Clinical
  • 15.5 Phase-0
  • 15.6 Phase-I
  • 15.7 Phase-I/II
  • 15.8 Phase-II
  • 15.9 Phase-II/III
  • 15.10 Phase-III
  • 15.11 Preregistration
  • 15.12 Registered

16. Marketed Cell Therapy Clinical Insight

  • 16.1 Immuncell-LC
  • 16.2 Adipocell (Anterogen)
  • 16.3 Provenge
  • 16.4 CureXcell
  • 16.5 Holoclar
  • 16.6 MACI
  • 16.7 Carticel
  • 16.8 MyoCell
  • 16.9 Laviv
  • 16.10 Prochymal
  • 16.11 Grafix
  • 16.12 Gintuit
  • 16.13 Autologous Mesenchymal Stem Cell Therapy - Pharmicell
  • 16.14 Cartistem
  • 16.15 CHONDRON
  • 16.16 BioCart
  • 16.17 NuCel
  • 16.18 Dendritic Cell-Activated Cytokine-Induced Killer Cells
  • 16.19 Chondrotransplant DISC
  • 16.20 Urocell
  • 16.21 CellSpray

17. Competitive Landscape

  • 17.1 AlloCure
  • 17.2 Arteriocyte Medical Systems
  • 17.3 Athersys Inc.
  • 17.4 Baxter Healthcare Corporation
  • 17.5 Bone Therapeutics
  • 17.6 Celgene Corporation
  • 17.7 Cell Medica
  • 17.8 Cellerant Therapeutics
  • 17.9 FibrocellScinence
  • 17.10 Forticell Bioscience
  • 17.11 Genzyme Corporation
  • 17.12 Green Cross Cell
  • 17.13 Histogenics Corporation
  • 17.14 InnovacellBiotechnologie AG
  • 17.15 Intrexon Corporation
  • 17.16 Intercytex
  • 17.17 ISTO Technologies
  • 17.18 Macrocure
  • 17.19 Mesoblast
  • 17.20 Molmed
  • 17.21 Nuo Therapeutics Inc
  • 17.22 OmniCyte
  • 17.23 Opexa Therapeutics
  • 17.24 Organogenesis
  • 17.25 Pharmicell
  • 17.26 TCA Cellular Therapy
  • 17.27 Stem Cell Inc.
  • 17.28 Teva Pharmaceuticals
  • 17.29 Tigenix
  • 17.30 Vericel Corporation

List of Figures

  • Figure 1-1: Basic Overview of Cell Therapy
  • Figure 1-2: Historical Insight into Cell Therapy
  • Figure 1-3: Key Goals of using Cell Therapy
  • Figure 2-1: Mechanism of Paracrine Signaling
  • Figure 2-2: Demonstration of the Endocrine Signaling
  • Figure 2-3: Illustration of the Autocrine Signaling
  • Figure 2-4: Paracrine Signaling in Heart Repair
  • Figure 2-5: Common Sources of Cells in Cell Therapy
  • Figure 2-6: Requirements of an Ideal Cell Donor in Cell Therapy
  • Figure 2-7: Steps in Allogeneic Stem Cell Therapy
  • Figure 2-8: Steps in Autologous Stem Cell Therapy
  • Figure 3-1: Application of Cell Therapy in Various Clinical Indications
  • Figure 3-2: Global - Cell Therapy Type by Donor Cell Source (%).2018
  • Figure 3-3: Global - Stem Cell v/s Non Stem Cell Therapy Studies (%), 2018
  • Figure 3-4: Type of Stem Cells on the Basis of Origin
  • Figure 3-5: Global - Cell Therapy Product Source (%), 2018
  • Figure 3-6: Type of Stem Cells & Their Ability to Differentiate
  • Figure 3-7: Global - Type of Immune Cells Used in Cell Therapy (%), 2018
  • Figure 4-1: Global - Mortality Caused by Non Communicable Disease (%), 2018
  • Figure 4-2: Cell Therapy - Clinical Trials by Indication (%), 2018
  • Figure 4-3: Cell Therapy for Cardiovascular Disease
  • Figure 4-4: Overview of Stem Cell Therapy in Cardiovascular Disease
  • Figure 4-5: Cell Therapy in Neurological Disorders
  • Figure 4-6: Cell Therapy in Treatment of Alzheimer's disease
  • Figure 4-7: Cell Therapy in Diabetes
  • Figure 5-1: Apligraf - Cost per Use (US$/Patient), 2018
  • Figure 5-2: Carticel - Price Analysis (US$/Patient), 2018
  • Figure 5-3: ChondroCelect - Price Analysis (US$/Patient), 2018
  • Figure 5-4: Epicel - Price Analysis per 1% Total Body Surface Area (US$/Patient), 2018
  • Figure 5-5: Kymriah - Therapy Price Analysis (US$/Year), 2018
  • Figure 5-6: Provenge - Price Analysis (US$/Year), 2018
  • Figure 5-7: Yescarta - Price Analysis (US$), 2018
  • Figure 6-1: Spherox - Price Analysis (US$/Patient), 2018
  • Figure 6-2: Strimvelis - Price Analysis (US$ & Euro), 2018
  • Figure 7-1: Cartistem - Price Analysis (US$/Dose), 2018
  • Figure 7-2: Hearticellgram - Price Analysis (US$/Patient), 2018
  • Figure 8-1: HeartSheet - Treatment Cost Analysis (US$/ Administration), 2018
  • Figure 8-2: Temcell - Price Analysis (US$/72 Million Cells), 2018
  • Figure 9-1: Global - Cell Therapy Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 9-2: Global - Cell Therapy Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 9-3: Global - Cell Therapy Clinical Pipeline by Discontinued Trials(%),2018 till 2024
  • Figure 9-4: Global - Cell Therapy Clinical Pipeline by Discontinued Trials (Number), 2018 till 2024
  • Figure 10-1: Global - Preference of Cell Type in Cell Therapy (%), 2018
  • Figure 10-2: Cell Therapy - Funding in Industry & Academia (%), 2018
  • Figure 12-1: Cell Therapy - Trials Conducted by Region (%), 2018
  • Figure 12-2: Europe - Cell Therapy Clinical Trial Analysis by Region (%), 2018
  • Figure 12-3: Asia - Cell Therapy Clinical Trial by Region (%), 2018
  • Figure 12-4: Cell Therapy-Comparative Cost Analysis by Region (US$), 2018
  • Figure 12-5: Rest of the World - Cell Therapy Clinical Trial by Region (%), 2018
  • Figure 13-1: Global - Key Factors Driving the Cell Therapy Market
  • Figure 13-2: Global - Cell Therapy Market Challenges
  • Figure 14-1: Future Objectives of the Cell Therapy market
  • Figure 14-2: Global - Cell Therapy Market Opportunity (US$ Billion), 2018 -2024
  • Figure 14-3: Key Developments Impacting the Future Cell Therapy Market
  • Figure 17-1: Arteriocyte Medical Systems Clinical Pipeline
  • Figure 17-2: Bone Therapeutics Clinical Pipeline
  • Figure 17-3: Celgene Clinical Pipeline
  • Figure 17-4: Cellerant Therapeutics Clinical Pipeline
  • Figure 17-5: Fibrocell Science Clinical Pipeline
  • Figure 17-6: Genzyme Clinical Pipeline
  • Figure 17-7: Intrexon Clinical Pipeline
  • Figure 17-8: ISTO Clinical Pipeline
  • Figure 17-9: Mesoblast Clinical Pipeline
  • Figure 17-10: Molmed Clinical Pipeline
  • Figure 17-11: Pharmicell Clinical Pipeline
  • Figure 17-12: Tigenix Clinical Pipeline
  • Figure 17-13: Vericel Corporation Clinical Pipeline
Back to Top
전화 문의
F A Q